Table 5.
Study | Population | N | HSV2 Ascertainment |
Outcome: CD4 COUNT (in cells/mm
3
) |
||||
---|---|---|---|---|---|---|---|---|
Outcome | HSV2 pos | HSV2 neg | Difference | Effect b | ||||
Studies in acute HIV seroconverters | ||||||||
Cachay 2008 |
Male HIV seroconverters, USA |
9 |
HSV2 seroconversion by WB |
Change in CD4 after vs before HSV-2 sero-conversion over 779 days |
−44 (range = −82,220) |
Reference: Before seroconversion |
p = 0.36 |
↔ |
Studies in chronic HIV infection | ||||||||
Crum-Cianflone 2006 |
USA |
271 |
Serology: Focus |
Change in CD4 at 1 year |
−116 |
+14 |
−130, p=0.003 |
↓ |
221 |
Change in CD4 at 3 years |
−227 |
−85 |
−142, p = 0.03 |
↓ |
|||
Roxby 2011 | Postpartum women, Kenya | 296 | Serology: Focus | Rate of change in CD4 over mean 18 months | −4.22/month | −3.42/month | −0.8/month p = 0.57 | ↔ |
aCI = confidence interval, IQR = interquartile range, NR = not reported, MSM = men who have sex with men, WB = Western Blot.
bArrows show directions of association with HSV-2; ‘?’ denotes borderline statistical significance or clinically significant differences not meeting statistical significance.